RxDoctor Payments Data

Lamar Wedderburn, DO

Internal Medicine · Orlando, FLNPI 1053802439

Payments from drug & device makers

$1,473in general payments, 2019–2025

Across 25 payments — averaging $58.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$299
  • Biohaven Pharmaceutical Holding Company Ltd.$240
  • Novo Nordisk$235
  • Amgen$177
  • Syndax Pharmaceuticals, Inc.$134
  • Boehringer Ingelheim$130
  • plus $258 from 4 others

What the payments were for

  • Food & beverage$1,473100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,473 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$90,824
Medicare patients
249
Services billed
822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$47,848
OzempicSemaglutide30$36,552
XareltoRivaroxaban14$18,558
TrulicityDulaglutide11$10,748
Rosuvastatin Calcium168$3,108
Levothyroxine Sodium129$2,082
Atorvastatin Calcium146$1,881
SynthroidLevothyroxine Sodium23$1,729
Tamsulosin Hcl75$1,541
Olmesartan Medoxomil56$1,304
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide22$1,288
Levocetirizine Dihydrochloride59$1,132
Metoprolol Succinate64$1,077
Valsartan27$1,049
Ezetimibe13$999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$130$47,84833 claims
Novo NordiskOzempic$235$36,55230 claims
Johnson & JohnsonXarelto$125$18,55814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →